ArticleACS omega2025
Influence of Yttrium (Y) Substitution in pH-Responsive 5‑Fluorouracil Delivery of Y-ZnO Nanoformulation.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rise in cancer fatalities necessitates the development of advanced treatments employing nanomaterials with better biocompatibility and efficacy. 5-Fluorouracil (5-FU), a pyrimidine analogue with potent antitumor effects, inhibits diverse solid tumors by blocking thymidylate synthase and incorporating its metabolites into RNA and DNA, preventing cancer cell proliferation. However, poor oral absorption and bioavailability limit its therapeutic efficiency. Hence, the development of a pH-stable carrier is imperative to bolster the efficacy and mitigate side effects. In this study, the synthesis of 0 to 15 wt % yttrium (Y)-doped ZnO nanostructures via the sol-gel process and the distinct characteristics from their pure counterparts have been reported. Y doping modifies the energy bandgap of ZnO, fosters oxygen vacancy formation, hinders crystal growth by reducing the energy bandgap, facilitates Y
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.